Actively Recruiting

Phase 4
Age: 18Years - 45Years
All Genders
Healthy Volunteers
ID06763172

Measure Striatal Adenosine-Dopamine Receptor Interactions from Molecules to Behaviors Using Caffeine and PET/MRI in Healthy Adults

Led by Hsiao-Ying Wey · Updated on 2025-01-09

12

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are investigating how caffeine intake influences the learning process through reward feedback compared to a placebo. This study focuses on healthy adults aged 18 to 45 and aims to better understand the role of caffeine in dopamine-related reinforcement learning. The research explores interactions between adenosine 2A receptors and dopamine D2 receptors in the brain, which are important for learning and behavior, using advanced brain imaging techniques. Participants will take part in a double-blind randomized crossover study where they receive either a 200mg caffeine tablet or a placebo lactose tablet. Before each study day, participants undergo a 6-day period without caffeine, alcohol, or drugs and maintain regular sleep schedules. On the seventh day, they undergo simultaneous PET/fMRI brain scans after taking the assigned tablet 20 minutes prior to scanning. These scans will measure dopamine receptor availability and brain activity during reinforcement learning and motor inhibition tasks. During the study visits, participants complete a Probabilistic Selection Task (reinforcement learning) and a Go/NoGo task (motor inhibition) while being scanned. Researchers monitor dopamine D2/D3 receptor availability with PET using a radioactive dye and brain activity with fMRI. The study also assesses salience attribution after scanning. Safety is monitored, and participants' adherence to the washout period is required. The main outcomes include dopamine receptor availability and effects of caffeine on learning tasks during the scan. The total participation includes the washout and scan days, with follow-up assessments after the scan.

CONDITIONS

Brief Title

Effects of Caffeine on Reinforcement Learning in Healthy Adults Using PET/MRI

Who Can Participate

Age: 18Years - 45Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 18 and 45 years
  • Habitual caffeine intake between 100 mg and 450 mg daily
  • Non-smokers
  • Clinically healthy
  • Have normal or corrected-to-normal vision
Not Eligible

You will not qualify if you...

  • Pregnant or lactating women
  • Women using hormonal contraceptives
  • Body mass index (BMI) less than 18.5 or greater than 29.9
  • Sleep disturbances or extreme chronotype
  • Positive urine test for drugs including benzoylecgonine, morphine, methamphetamine, amphetamine, benzodiazepines, secobarbital, methadone, buprenorphine glucuronide, nortriptyline, MDMA, oxycodone, PCP, propoxyphene, and cannabis/THC
  • Diagnosis of depression, anxiety, psychosis, or neurological disorders in the last 5 years
  • Heart or cardiovascular diseases
  • Diabetes or other metabolic diseases
  • Use of chronic medications such as painkillers or steroids
  • Allergy to lactose (placebo ingredient)
  • Inability to operate tasks or understand study information in English
  • Presence of metallic foreign bodies like pacemakers or aneurysm clips
  • Likelihood of seizures or severe claustrophobia
  • Inability to lie flat for about 90 minutes
  • Recent exposure to radiation exceeding allowable limits
  • Body weight over 300 lbs (MRI scanner limit)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Washout Period

Duration - 6 days

Participants abstain from caffeinated dietary sources, alcohol, and drugs while maintaining regular bed and wake times.

Daily ambulatory period with no visits

Treatment

Duration - 1 day

Participants receive either a caffeine or placebo tablet 20 minutes prior to a PET/fMRI scan to assess the effects on reinforcement learning and dopamine receptor availability.

1 visit (in-person PET/fMRI scan day)

Washout Period

Duration - 6 days

Participants abstain from caffeinated dietary sources, alcohol, and drugs while maintaining regular bed and wake times before crossing over to the other treatment condition.

Daily ambulatory period with no visits

Treatment

Duration - 1 day

Participants receive the alternate treatment (caffeine or placebo) 20 minutes prior to a PET/fMRI scan to assess the effects on reinforcement learning and dopamine receptor availability.

1 visit (in-person PET/fMRI scan day)

Trial Site Locations

Total: 1 location

1

Athinoula A. Martinos Center for Biomedical Imaging

Charlestown, Massachusetts, United States, 02129

Actively Recruiting

Loading map...

Research Team

H

Hsiao-Ying Wey, PhD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

BASIC_SCIENCE

Number of Arms

2

Similar Trials

Multifactorial Risk Stratification in Acute and Chronic Card...

Cardiovascular Diseases

Actively Recruiting

2 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Published Research Related To This Trial

From neuroimaging to daily functioning: A multimethod analysis of reward anticipation in people with schizophrenia.

Erin K Moran, Adam J Culbreth, Sridhar Kandala...

https://pubmed.ncbi.nlm.nih.gov/31464449